BBIO vs SO · rev $221.9M vs P/E 22, rev $29.55B
BridgeBio Pharma Inc (BBIO) versus Southern Company (SO) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Southern Company (SO) is a utilities - regulated electric company listed on US.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported SO revenue for 2025-12-31 was $29.55B. Net income was $4.34B. Revenue was up 10.6% from 2024-12-31 to 2025-12-31. SO currently screens at market cap $101.55B and trailing P/E 22.1.
BBIO currently screens at market cap $13.24B. SO currently screens at market cap $101.55B and trailing P/E 22.1.
Not investment advice. Open the BBIO and SO stock pages for the full models.
Not investment advice.